Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus.
OBJECTIVE
Infliximab has been approved for the treatment of chronic plaque psoriasis for only a few years. As physicians gain confidence in initiating and maintaining this therapy, guidance on the management of patients beyond several months or years is needed. To date, there is little or no information about the long-term management in clinical trials or guidelines.


METHODS
Here we report on the key aspects related to the use of infliximab for the treatment of psoriasis. The data presented here were derived using a modified Delphi survey to obtain a consensus opinion of 11 dermatologists from Europe and Canada experienced in long-term therapy with infliximab.


CONCLUSIONS
The Delphi participants reviewed several important topics related to biological therapy and infliximab. This paper is not intended to provide a recommendation on all practical aspects related to biological therapy; it has rather been written to provide useful and practical information on the 'best practice' use of infliximab.
Reich
Kristian
K
Department of Dermatology, Dermatologikum Hamburg, Hamburg, Germany. reich@dermatologikum.de
Griffiths
Christopher
C
Barker
Jonathan
J
Chimenti
Sergio
S
Daudén
Esteban
E
Giannetti
Alberto
A
Gniadecki
Robert
R
Katsambas
Andreas
A
Langley
Richard
R
Mrowietz
Ulrich
U
Ogilvie
Alexandra
A
Ortonne
Jean-Paul
JP
Reider
Norbert
N
Saurat
Jean-Hilaire
JH
D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003697:Delphi Technique; D003879:Dermatologic Agents / Q000008:administration & dosage*; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy*; D011795:Surveys and Questionnaires
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab